CAS 141-90-2|2-Thiouracil
| Common Name | 2-Thiouracil | ||
|---|---|---|---|
| CAS Number | 141-90-2 | Molecular Weight | 128.152 |
| Density | 1.5±0.1 g/cm3 | Boiling Point | 337.2ºC at 760mmHg |
| Molecular Formula | C4H4N2OS | Melting Point | >300 °C(lit.) |
| MSDS | ChineseUSA | Flash Point | 157.7ºC |
| Symbol | GHS08 | Signal Word | Warning |
Names
| Name | thiouracil |
|---|---|
| Synonym | More Synonyms |
2-Thiouracil BiologicalActivity
| Description | 2-Thiouracil is a thiolated uracil derivative that is a known antihyperthyroid agent. Target: Others2-Thiouracil is an established antithyroid drug and an extensively investigated agent for the early detection and targeting of metastatic melanotic melanoma. In addition, 2-Thiouracil is also a selective inhibitor of neuronal nitric oxide synthase antagonising tetrahydrobiopterin-dependent enzyme activation and dimerization. Thiouracil refers both to a specific molecule consisting of a sulfated uracil, and a family of molecules based upon that structure. Thiouracil inhibits thyroid activity by blocking the enzyme thyroid peroxidase [1-3]. |
|---|---|
| Related Catalog | Signaling Pathways >>Others >>OthersResearch Areas >>Endocrinology |
| References | [1]. Palumbo, A., M. d'Ischia, and F.A. Cioffi, 2-thiouracil is a selective inhibitor of neuronal nitric oxide synthase antagonising tetrahydrobiopterin-dependent enzyme activation and dimerisation. FEBS Lett, 2000. 485(2-3): p. 109-12. [2]. Napolitano, A., et al., Mechanism of selective incorporation of the melanoma seeker 2-thiouracil into growing melanin. J Med Chem, 1996. 39(26): p. 5192-201. [3]. Nagasaka, A. and H. Hidaka, Effect of antithyroid agents 6-propyl-2-thiouracil and 1-mehtyl-2-mercaptoimidazole on human thyroid iodine peroxidase. J Clin Endocrinol Metab, 1976. 43(1): p. 152-8. |
Chemical & Physical Properties
| Density | 1.5±0.1 g/cm3 |
|---|---|
| Boiling Point | 337.2ºC at 760mmHg |
| Melting Point | >300 °C(lit.) |
| Molecular Formula | C4H4N2OS |
| Molecular Weight | 128.152 |
| Flash Point | 157.7ºC |
| Exact Mass | 128.004440 |
| PSA | 80.74000 |
| LogP | -0.28 |
| Vapour Pressure | 5.45E-05mmHg at 25°C |
| Index of Refraction | 1.678 |
| InChIKey | ZEMGGZBWXRYJHK-UHFFFAOYSA-N |
| SMILES | O=c1cc[nH]c(=S)[nH]1 |
| Storage condition | 2-8°C |
| Water Solubility | 0.5 g/L |
Toxicological Information
CHEMICAL IDENTIFICATION |
ACUTE TOXICITY DATA - TYPE OF TEST :
- LDLo - Lowest published lethal dose
- ROUTE OF EXPOSURE :
- Intraperitoneal
- SPECIES OBSERVED :
- Rodent - rat
- DOSE/DURATION :
- 1500 mg/kg
- TOXIC EFFECTS :
- Details of toxic effects not reported other than lethal dose value
- TYPE OF TEST :
- LD50 - Lethal dose, 50 percent kill
- ROUTE OF EXPOSURE :
- Oral
- SPECIES OBSERVED :
- Rodent - mouse
- DOSE/DURATION :
- 3900 mg/kg
- TOXIC EFFECTS :
- Details of toxic effects not reported other than lethal dose value
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Oral
- SPECIES OBSERVED :
- Rodent - rat
- DOSE/DURATION :
- 2100 mg/kg/4W-C
- TOXIC EFFECTS :
- Endocrine - changes in thyroid weight
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Oral
- SPECIES OBSERVED :
- Rodent - rat
- DOSE/DURATION :
- 10 gm/kg/14W-C
- TOXIC EFFECTS :
- Tumorigenic - equivocal tumorigenic agent by RTECS criteria Endocrine - thyroid weight (goiter) Tumorigenic - increased incidence of tumors in susceptible strains
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Oral
- SPECIES OBSERVED :
- Rodent - mouse
- DOSE/DURATION :
- 184 gm/kg/73W-C
- TOXIC EFFECTS :
- Tumorigenic - neoplastic by RTECS criteria Liver - tumors
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Unreported
- DOSE :
- 484 mg/kg
- SEX/DURATION :
- female 1-26 week(s) after conception
- TOXIC EFFECTS :
- Reproductive - Specific Developmental Abnormalities - endocrine system
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Unreported
- DOSE :
- 924 mg/kg
- SEX/DURATION :
- female 26-41 week(s) after conception
- TOXIC EFFECTS :
- Reproductive - Specific Developmental Abnormalities - Central Nervous System Reproductive - Specific Developmental Abnormalities - craniofacial (including nose and tongue) Reproductive - Effects on Newborn - viability index (e.g., # alive at day 4 per # born alive)
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Oral
- DOSE :
- 1600 mg/kg
- SEX/DURATION :
- female 1-16 day(s) after conception
- TOXIC EFFECTS :
- Reproductive - Specific Developmental Abnormalities - musculoskeletal system
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Oral
- DOSE :
- 22750 mg/kg
- SEX/DURATION :
- female 91 day(s) pre-mating
- TOXIC EFFECTS :
- Reproductive - Specific Developmental Abnormalities - endocrine system Reproductive - Effects on Newborn - growth statistics (e.g.%, reduced weight gain)
MUTATION DATA - TYPE OF TEST :
- Phage inhibition capacity
- TEST SYSTEM :
- Bacteria - Escherichia coli
- DOSE/DURATION :
- 100 mmol/L
- REFERENCE :
- MDMIAZ Medycyna Doswiadczalna i Mikrobiologia. For English translation, see EXMMAV. (Ars Polona, POB 1001, 00-068 Warsaw 1, Poland) V.1- 1949- Volume(issue)/page/year: 31,11,1979 *** REVIEWS *** IARC Cancer Review:Animal Limited Evidence IMEMDT IARC Monographs on the Evaluation of Carcinogenic Risk of Chemicals to Man. (WHO Publications Centre USA, 49 Sheridan Ave., Albany, NY 12210) V.1- 1972- Volume(issue)/page/year: 7,85,1974 IARC Cancer Review:Human No Adequate Data IMEMDT IARC Monographs on the Evaluation of Carcinogenic Risk of Chemicals to Man. (WHO Publications Centre USA, 49 Sheridan Ave., Albany, NY 12210) V.1- 1972- Volume(issue)/page/year: 7,85,1974 IARC Cancer Review:Group 3 IMSUDL IARC Monographs, Supplement. (WHO Publications Centre USA, 49 Sheridan Ave., Albany, NY 12210) No.1- 1979- Volume(issue)/page/year: 7,56,1987 TOXICOLOGY REVIEW ADVPA3 Advances in Pharmacology. (New York, NY) V.1-6, 1962-68. For publisher information, see AVPCAQ. Volume(issue)/page/year: 4,263,1966 *** NIOSH STANDARDS DEVELOPMENT AND SURVEILLANCE DATA *** NIOSH OCCUPATIONAL EXPOSURE SURVEY DATA : NOES - National Occupational Exposure Survey (1983) NOES Hazard Code - E0277 No. of Facilities: 6 (estimated) No. of Industries: 2 No. of Occupations: 2 No. of Employees: 1776 (estimated) No. of Female Employees: 634 (estimated)
- TYPE OF TEST :
- Phage inhibition capacity
- TEST SYSTEM :
- Bacteria - Escherichia coli
- DOSE/DURATION :
- 100 mmol/L
- REFERENCE :
- MDMIAZ Medycyna Doswiadczalna i Mikrobiologia. For English translation, see EXMMAV. (Ars Polona, POB 1001, 00-068 Warsaw 1, Poland) V.1- 1949- Volume(issue)/page/year: 31,11,1979 *** REVIEWS *** IARC Cancer Review:Animal Limited Evidence IMEMDT IARC Monographs on the Evaluation of Carcinogenic Risk of Chemicals to Man. (WHO Publications Centre USA, 49 Sheridan Ave., Albany, NY 12210) V.1- 1972- Volume(issue)/page/year: 7,85,1974 IARC Cancer Review:Human No Adequate Data IMEMDT IARC Monographs on the Evaluation of Carcinogenic Risk of Chemicals to Man. (WHO Publications Centre USA, 49 Sheridan Ave., Albany, NY 12210) V.1- 1972- Volume(issue)/page/year: 7,85,1974 IARC Cancer Review:Group 3 IMSUDL IARC Monographs, Supplement. (WHO Publications Centre USA, 49 Sheridan Ave., Albany, NY 12210) No.1- 1979- Volume(issue)/page/year: 7,56,1987 TOXICOLOGY REVIEW ADVPA3 Advances in Pharmacology. (New York, NY) V.1-6, 1962-68. For publisher information, see AVPCAQ. Volume(issue)/page/year: 4,263,1966 *** NIOSH STANDARDS DEVELOPMENT AND SURVEILLANCE DATA *** NIOSH OCCUPATIONAL EXPOSURE SURVEY DATA : NOES - National Occupational Exposure Survey (1983) NOES Hazard Code - E0277 No. of Facilities: 6 (estimated) No. of Industries: 2 No. of Occupations: 2 No. of Employees: 1776 (estimated) No. of Female Employees: 634 (estimated)
Safety Information
| Symbol | GHS08 |
|---|---|
| Signal Word | Warning |
| Hazard Statements | H351 |
| Precautionary Statements | P281 |
| Personal Protective Equipment | Eyeshields;full-face particle respirator type N100 (US);Gloves;respirator cartridge type N100 (US);type P1 (EN143) respirator filter;type P3 (EN 143) respirator cartridges |
| Hazard Codes | Xn:Harmful |
| Risk Phrases | R40 |
| Safety Phrases | S36/37 |
| RIDADR | NONH for all modes of transport |
| WGK Germany | 3 |
| RTECS | YR1575000 |
| HS Code | 29335995 |
Customs
| HS Code | 2933599090 |
|---|---|
| Summary | 2933599090. other compounds containing a pyrimidine ring (whether or not hydrogenated) or piperazine ring in the structure. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0% |
Articles34
More Articles| Identifying chelators for metalloprotein inhibitors using a fragment-based approach. J. Med. Chem. 54 , 591-602, (2011) Fragment-based lead design (FBLD) has been used to identify new metal-binding groups for metalloenzyme inhibitors. When screened at 1 mM, a chelator fragment library (CFL-1.1) of 96 compounds produced... | |
| Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors. J. Med. Chem. 51 , 6740-51, (2008) The work provides a new model for the prediction of the MAO-A and -B inhibitor activity by the use of combined complex networks and QSAR methodologies. On the basis of the obtained model, we prepared ... | |
| Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models. Toxicol. Mech. Methods 18 , 217-27, (2008) ABSTRACT Drug-induced phospholipidosis (PL) is a condition characterized by the accumulation of phospholipids and drug in lysosomes, and is found in a variety of tissue types. PL is frequently manifes... |
Synonyms
| 2-Thioxo-1,2,3,4-tetrahydropyrimidin-4-one |
| tiouracyl |
| TU |
| 2-Thiouracil |
| 2,3-dihydro-2-thioxo-(1H)pyrimidin-4-one |
| 4(1H)-Pyrimidinone, 2,3-dihydro-2-thioxo- |
| 2-Mercapto-4-pyrimidone |
| 2-Sulfanylpyrimidin-4(3H)-one |
| uracil, 2-thio- |
| THIURACIL |
| 2-Thioxo-2,3-dihydro-4(1H)-pyrimidinone |
| 2-TU |
| Nobilen |
| Thiouracil |
| 2-Mercapto-4-hydroxypyrimidine |
| 4(3H)-pyrimidinone, 2-mercapto- |
| 2-Thioxo-2,3-dihydropyrimidin-4(1H)-one |
| 4-Hydroxy-2-mercaptopyrimidine |
| 4-oxo-2-thioxo-1,2,3,4-tetrahydropyrimidine |
| EINECS 205-508-8 |
| Thiouraci |
| MFCD00006039 |
| DERACIL |
| 2-sulfanylpyrimidin-4-ol |
